about
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptorDefining the fitness of HIV-1 isolates with dual/mixed co-receptor usageAnalysis of primary resistance mutations to HIV-1 entry inhibitors in therapy naive subtype C HIV-1 infected mother-infant pairs from Zambia.Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops.HIV-1 drug discovery: targeting folded RNA structures with branched peptides.Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketFunctional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120Identification of Vimentin as a Potential Therapeutic Target against HIV InfectionTranscription activator like effector (TALE)-directed piggyBac transposition in human cellsTemplate-constrained cyclic sulfopeptide HIV-1 entry inhibitorsHuman immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition.Chronic hepatitis B: A wave of new therapies on the horizon.HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action.The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.A novel view of modelling interactions between synthetic and biological polymers via docking.Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins
P2860
Q27684529-1F53B953-FDB7-4DB0-8591-573469842107Q30278577-8E8888AE-5957-420A-AB40-EFB2C45579AEQ33597247-2553A82E-D1A1-4C94-9D4A-C2ED7AC5BA63Q34490720-5559E84D-94F8-4C85-A3FA-43A5FAAF7754Q35626292-A422F30D-8B88-423B-B867-177508EBE04CQ35641194-7F02A662-F7C6-4B6E-A088-ABADEE7A603AQ35858649-3DFDDBD1-DAB3-4F58-9281-59153E556842Q35878689-803D7A5A-F47D-4484-A366-E3E9F8A2E462Q36334376-768A5D5A-4129-4480-8139-2A0DBE8228FDQ36559608-085DD8E8-C0F5-4C54-B6FE-6DA4E286498FQ37049947-DFE99EB1-44E3-4616-9AEA-7E4FBC820039Q37236764-A84BDE27-FAD7-4D6D-8EFB-360510184C83Q37469187-E67E3A5C-976C-4958-8B79-CA9EA9349FA3Q38014473-FCFDC866-980E-4F54-8DAD-798500CDC2F1Q38076139-19C958A1-BEC3-42D2-97BD-CE9041C246FCQ38079744-1404E836-4DC5-4267-805B-38B05D0076A1Q38538107-5BE8839A-2C7E-46D1-9016-24B58833CC1EQ40797960-AB5310F9-52C4-4B3A-A5F8-D730E0BB9120Q41870119-13F50593-CB6A-408D-8CCE-18E99D775036Q42213760-A53F07C7-9AD9-41AE-B798-0DBC3035426BQ44536459-C73C2C2F-0F0D-489C-8F1B-393FE3B59646Q52656996-D890EC79-F35E-4F99-95A1-BD02E06EAD3BQ58555325-5AC3DE9A-38A3-4032-8C35-45B5AE02D52C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
HIV-1 Entry, Inhibitors, and Resistance
@en
HIV-1 Entry, Inhibitors, and Resistance.
@nl
type
label
HIV-1 Entry, Inhibitors, and Resistance
@en
HIV-1 Entry, Inhibitors, and Resistance.
@nl
prefLabel
HIV-1 Entry, Inhibitors, and Resistance
@en
HIV-1 Entry, Inhibitors, and Resistance.
@nl
P2093
P2860
P356
P1433
P1476
HIV-1 Entry, Inhibitors, and Resistance
@en
P2093
Annette N Ratcliff
Eric J Arts
Michael A Lobritz
P2860
P304
P356
10.3390/V2051069
P577
2010-04-29T00:00:00Z